Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma-Reference-Cited by-同舟云学术

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Published:2020-07-15 Issue:12 Volume:61 Page:2939-2946
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Soumerai Jacob D.¹²^ORCID,Ni Andy¹,Alperovich Anna¹,Batlevi Connie¹,Bantilan Kurt S.¹,Fischer Thais¹,Copeland Amanda R.¹,Smith Katy³,Ying Zhitao⁴,Younes Anas¹,Zelenetz Andrew D.¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Massachusetts General Hospital Cancer Center, Boston, MA, USA

3. Royal Marsden Hospital, London, UK

4. Peking University Cancer Hospital, Beijing, China

Funder

Lymphoma Research Foundation

Clinical Investigator Career Development Award

Lymphoma Clinical Research Mentoring Program

NIH/NCI

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1791850

Reference24 articles.

1. No Initial Therapy for Stage III and IV Non-Hodgkin's Lymphomas of Favorable Histologic Types

2. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

3. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

4. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection;Leukemia & Lymphoma;2022-12-12